Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer: The Clinical Impact of Immune Checkpoint Inhibitors—A Systematic Review — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer: The Clinical Impact of Immune Checkpoint Inhibitors—A Systematic Review
Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
,
Department of Surgery, Thaa Atoll Hospital, Veymandoo, Maldives
,
Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
,
Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
,
Department of Surgery, Shahid Syed Nazrul Islam College, Mymensingh, Bangladesh
,
Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
,
Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
,
Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
1 Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
2 Department of Surgery, Thaa Atoll Hospital, Veymandoo, Maldives
3 Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
4 Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
5 Department of Surgery, Shahid Syed Nazrul Islam College, Mymensingh, Bangladesh
6 Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
7 Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
8 Department of Surgery, Jalalabad Ragib-Rabeya Medical College Hospital, Sylhet, Bangladesh
Background: Neoadjuvant immunotherapy, particularly immune checkpoint inhibitors (ICIs), has emerged as a promising therapeutic strategy in the treatment of Triple-Negative breast cancer (TNBC). This systematic review evaluates the clinical impact of ICIs in combination with neoadjuvant chemotherapy, focusing on their improving pathological complete response (pCR) rates and outcomes. This review was conducted using PRISMA guidelines. A comprehensive literature search was conducted across multiple databases, including PubMed, Google Scholar, and EMBASE, for studies evaluating the use of ICIs in neoadjuvant therapy regimens for early-stage TNBC. Overall, while neoadjuvant ICIs represent a potential breakthrough in TNBC treatment, further clinical trials and long-term data are necessary to better define their role in improving patient outcomes.
KeywordsNeoadjuvant ImmunotherapyCheckpoint InhibitorsTriple Negative Breast Cancer (TNBC)
Foulkes, W.D., Smith, I.E. and Reis-Filho, J.S. (2010) Triple-Negative Breast Cancer. New England Journal of Medicine , 363, 1938-1948. https://doi.org/10.1056/nejmra1001389
Tian, Q., Du, P., Li, S., Bai, Z., Yang, Y. and Zeng, J. (2017) Effect of Antitumor Treatments on Triple-Negative Breast Cancer Patients. Medicine , 96, e8389. https://doi.org/10.1097/md.0000000000008389
Schmid, P., Rugo, H.S., Adams, S., Schneeweiss, A., Barrios, C.H., Iwata, H., et al . (2020) Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (Impassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology , 21, 44-59. https://doi.org/10.1016/s1470-2045(19)30689-8
Cortes, J., Cescon, D.W., Rugo, H.S., et al . (2020) Pembrolizumab Plus Chemotherapy versus Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial. The Lancet , 396, 1817-1828.
Schmid, P., Adams, S., Rugo, H.S., Schneeweiss, A., Barrios, C.H., Iwata, H., et al . (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine , 379, 2108-2121. https://doi.org/10.1056/nejmoa1809615
Loibl, S., Untch, M., Burchardi, N., et al . (2019) A Randomised Phase II Study Investigating Durvalumab in Addition to an Anthracycline Taxane-Based Neoadjuvant Therapy in Early Triple-Negative Breast Cancer: Clinical Results and Biomarker Analysis of Geparnuevo Study. Annals of Oncology , 30, 1279-1288. https://doi.org/10.1093/annonc/mdz158
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., et al . (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine , 382, 810-821. https://doi.org/10.1056/nejmoa1910549
Nanda, R., Liu, M.C., Yau, C., Shatsky, R., Pusztai, L., Wallace, A., et al . (2020) Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer. JAMA Oncology , 6, 676-684. https://doi.org/10.1001/jamaoncol.2019.6650
Mittendorf, E.A., Zhang, H., Barrios, C.H., Saji, S., Jung, K.H., Hegg, R., et al . (2020) Neoadjuvant Atezolizumab in Combination with Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy versus Placebo and Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer (Impassion031): A Randomized, Double-Blind, Phase 3 Trial. The Lancet , 396, 1090-1100. https://doi.org/10.1016/s0140-6736(20)31953-x
Gianni, L., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., et al . (2020) Abstract GS3-04: Pathologic Complete Response (pCR) to Neoadjuvant Treatment with or without Atezolizumab in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer. Neotripapdl1 Michelangelo Randomized Study. Cancer Research , 80, GS3-04. https://doi.org/10.1158/1538-7445.sabcs19-gs3-04
Ademuyiwa, F.O., Gao, F., Chen, I., Northfelt, D.W., Wesolowski, R., Arora, M., et al . (2021) Abstract PD14-09: Nci 10013—A Randomized Phase 2 Study of Neoadjuvant Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (tnbc). Cancer Research , 81, PD14-09. https://doi.org/10.1158/1538-7445.sabcs20-pd14-09
Lyons, T.G. (2019) Targeted Therapies for Triple-Negative Breast Cancer. Current Treatment Options in Oncology , 20, Article No. 82. https://doi.org/10.1007/s11864-019-0682-x
Hutchinson, K.E., Yost, S.E., Chang, C., Johnson, R.M., Carr, A.R., McAdam, P.R., et al . (2020) Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts. Clinical Cancer Research , 26, 657-668. https://doi.org/10.1158/1078-0432.ccr-19-1773
Szekely, B., Bossuyt, V., Li, X., Wali, V.B., Patwardhan, G.A., Frederick, C., et al . (2018) Immunological Differences between Primary and Metastatic Breast Cancer. Annals of Oncology , 29, 2232-2239. https://doi.org/10.1093/annonc/mdy399
Pardoll, D.M. (2012) The Blockade of Immune Checkpoints in Cancer Immunotherapy. Nature Reviews Cancer , 12, 252-264. https://doi.org/10.1038/nrc3239
Keir, M.E., Butte, M.J., Freeman, G.J. and Sharpe, A.H. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology , 26, 677-704. https://doi.org/10.1146/annurev.immunol.26.021607.090331
Nishimura, H., Agata, Y., Kawasaki, A., Sato, M., Imamura, S., Minato, N., et al . (1996) Developmentally Regulated Expression of the PD-1 Protein on the Surface of Double-Negative (CD4–CD8–) Thymocytes. International Immunology , 8, 773-780. https://doi.org/10.1093/intimm/8.5.773
Topalian, S.L., Drake, C.G. and Pardoll, D.M. (2012) Targeting the PD-1/B7-H1(PD-L1) Pathway to Activate Anti-Tumor Immunity. Current Opinion in Immunology , 24, 207-212. https://doi.org/10.1016/j.coi.2011.12.009
Taube, J.M., Anders, R.A., Young, G.D., Xu, H., Sharma, R., McMiller, T.L., et al . (2012) Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine , 4, 127ra37. https://doi.org/10.1126/scitranslmed.3003689
Mittendorf, E.A., Philips, A.V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., et al . (2014) PD-L1 Expression in Triple-Negative Breast Cancer. Cancer Immunology Research , 2, 361-370. https://doi.org/10.1158/2326-6066.cir-13-0127
Narayan, P., Wahby, S., Gao, J.J., Amiri-Kordestani, L., Ibrahim, A., Bloomquist, E., et al. (2020) FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-Bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express Pd-l1. Clinical Cancer Research , 26, 2284-2289. https://doi.org/10.1158/1078-0432.ccr-19-3545
Budd, G.T., Barlow, W.E., Moore, H.C.F., Hobday, T.J., Stewart, J.A., Isaacs, C., et al . (2015) SWOG S0221: A Phase III Trial Comparing Chemotherapy Schedules in High-Risk Early-Stage Breast Cancer. Journal of Clinical Oncology , 33, 58-64. https://doi.org/10.1200/jco.2014.56.3296
Gianni, L., Huang, C.S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., et al . (2022) Pathologic Complete Response (PCR) to Neoadjuvant Treatment with or without Atezolizumab in Triple-Negative, Early High-Risk and Locally Advanced Breast Cancer: Neotrip Michelangelo Randomized Study. Annals of Oncology , 33, 534-543. https://doi.org/10.1016/j.annonc.2022.02.004
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., et al . (2022) Neoadjuvant Durvalumab Improves Survival in Early Triple-Negative Breast Cancer Independent of Pathological Complete Response. Annals of Oncology , 33, 1149-1158. https://doi.org/10.1016/j.annonc.2022.07.1940
Won, K. and Spruck, C. (2020) Triplenegative Breast Cancer Therapy: Current and Future Perspectives (review). International Journal of Oncology , 57, 1245-1261. https://doi.org/10.3892/ijo.2020.5135
Mougalian, S.S., Soulos, P.R., Killelea, B.K., Lannin, D.R., Abu-Khalaf, M.M., DiGiovanna, M.P., et al . (2015) Use of Neoadjuvant Chemotherapy for Patients with Stage I to III Breast Cancer in the United States. Cancer , 121, 2544-2552. https://doi.org/10.1002/cncr.29348
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J.P., Wolmark, N., et al . (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis. The Lancet , 384, 164-172. https://doi.org/10.1016/s0140-6736(13)62422-8
U.S. Department of Health and Human Services, Food and Drug Administration, Oncology Center of Excellence, CDER and CBER (2020) Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval Guidance for Industry. https://www.fda.gov/media/83507/download
Patrinely, J.R., Johnson, R., Lawless, A.R., Bhave, P., Sawyers, A., Dimitrova, M., et al . (2021) Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma. JAMA Oncology , 7, 744-748. https://doi.org/10.1001/jamaoncol.2021.0051
Chen, C., Yu, H. and Yu, S. (2022) Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article. Current Oncology , 29, 2871-2886. https://doi.org/10.3390/curroncol29040234
Brahmer, J.R., Lacchetti, C., Schneider, B.J., Atkins, M.B., Brassil, K.J., Caterino, J.M., et al . (2018) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology , 36, 1714-1768. https://doi.org/10.1200/jco.2017.77.6385